462 studies found for:    "Chronic myelomonocytic leukemia"
Show Display Options
Rank Status Study
1 Unknown  Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Revlimid
2 Completed Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Decitabine
3 Active, not recruiting Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: Decitabine
4 Active, not recruiting A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention: Drug: 5-Azacitidine
5 Completed A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Conditions: Myelofibrosis;   Myeloid Metaplasia;   Agnogenic Myeloid Metaplasia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: Imatinib mesylate
6 Active, not recruiting A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Conditions: Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Acute Myeloid Leukemia
Interventions: Drug: Panobinostat (LBH589) and 5-Azacytidine;   Drug: 5-Azacytidine
7 Active, not recruiting Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
Conditions: Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Acute Myelogenous Leukemia (AML)
Interventions: Drug: Subcutaneous (SC) Azacitidine;   Drug: Oral Azacitidine
8 Active, not recruiting A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
Conditions: Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Acute Myeloid Leukemia (AML)
Intervention: Drug: Panobinostat
9 Recruiting Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
Conditions: Anemia;   Myelodysplastic Syndromes (MDS);   Chronic Myelomonocytic Leukemia (CMML);   Low to Intermediate-1 MDS
Intervention: Drug: Sotatercept
10 Recruiting The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
Condition: Chronic Myelomonocytic Leukemia
Intervention:
11 Completed Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Myelodysplastic Syndromes;   Secondary Myelodysplastic Syndromes
Intervention: Drug: sunitinib malate
12 Suspended Azacitidine With or Without Lenalidomide or Vorinostat in Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Secondary Myelodysplastic Syndromes
Interventions: Drug: azacitidine;   Drug: lenalidomide;   Drug: vorinostat
13 Active, not recruiting Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Conditions: Cancer;   Chronic Myelomonocytic Leukemia
Intervention: Drug: Clofarabine
14 Completed Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myelogenous Leukemia
Intervention: Drug: Imatinib
15 Terminated Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
Conditions: Acute Myelogenous Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: DTGM
16 Active, not recruiting Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: entinostat;   Drug: azacitidine
17 Active, not recruiting MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: azacitidine;   Drug: entinostat
18 Completed
Has Results
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Essential Thrombocythemia;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Polycythemia Vera;   Primary Myelofibrosis;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: fludarabine phosphate;   Drug: triapine;   Procedure: laboratory biomarker analysis
19 Completed Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Conditions: Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia
Interventions: Drug: Azacitidine;   Drug: Erythropoetin
20 Completed Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate
Conditions: Chronic Myelomonocytic Leukemia;   Chronic Myeloid Leukemia;   Polycythemia Vera;   Hypereosinophilic Syndrome;   Mastocytosis
Intervention: Drug: Imatinib Mesylate (Gleevec)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years